Application of substance for detecting content of serum angiopoetin-like protein 2 in preparation of product for detecting hepatitis and fibrosis degree

Abstract

The invention discloses an application of a substance for detecting the content of a serum angiopoetin-like protein 2 (angptl2) in preparation of a product for detecting hepatitis and fibrosis degree. Experiments find out that the content of the angptl2 in serum has correlation with the hepatitis degree and fibrosis degree of a chronic hepatitis B virus infected patient, the content of the angptl2 can be used as a noninvasive single indicator for judging the hepatitis degree and fibrosis degree, the substance for detecting the content of the serum angptl2 or a substance for detecting other common clinical indicators of hepatopath can be combined together to prepare the product for detecting the human hepatitis degree and / or fibrosis degree, a product for diagnosing or auxiliarily diagnosing whether patients with hepatopathy need liver biopsy detection or a product for screening or auxiliarily screening the patients with hepatopathy who need or do not need liver biopsy.

Description

technical field [0001] The invention relates to the application of a substance for detecting serum angiopoietin-like protein 2 content in the preparation of products for detecting liver inflammation and fibrosis degree in the field of biomedicine. Background technique [0002] Asia-Pacific and American Association of Liver Diseases recommendations on treatment decision-making guidelines for patients with chronic hepatitis B virus (HBV) infection: ALT ≥ 2ULN, HBV DNA ≥ 20000IU / mL (HBeAg-positive) or HBV DNA ≥ 2000IU / mL (HBeAg-negative) HBV-infected patients need to be given antiviral treatment. For patients in the gray zone who do not meet the above cut-off values, it is necessary to assist in determining the treatment plan based on the pathological results of liver biopsy. Liver puncture pathology shows moderate to severe inflammation or obvious fibrosis requires immediate antiviral treatment. However, liver biopsy is an invasive examination, with interpretation and sampli...

AI Technical Summary

Problems solved by technology

However, liver biopsy is an invasive examination, with errors in interpretation and sampling, and risks of bleeding and bile leakage, so it is not suitable for all patients

However, the existing non-invasive methods are only suitable for judging the degree of liver fibrosis, and the research population only focuses on patients with chronic hepatitis B, and are not suitable for judging treatment decisions for all patients with chronic HBV infection

Images